Our Business
Providing breakthrough treatments
for patients around the world
From mental health conditions to neurological disorders
In the central nervous system (CNS) field, building on the success of our globally recognized antipsychotic drug ABILIFY, in 2013 we launched ABILIFY Maintena, a once-monthly, extended-release antipsychotic injection, in the U.S. and it is now sold in over 50 countries.
REXULTI, a new antipsychotic drug approved by the FDA in the U.S. for the treatment of schizophrenia and an adjunctive treatment for major depressive disorder, was launched in 2015. It subsequently revived regulatory approval for use in schizophrenia in other countries, including in Japan and Europe in 2018, and is now sold in approximately 60 countries worldwide.
Avanir Pharmaceuticals in the U.S., acquired by Otsuka in 2015, markets in the U.S. NUEDEXTA, a treatment for the neurologic disease pseudobulbar affect (PBA). Avanir is also developing agents for treating symptoms of Alzheimer's type dementia and Parkinson's disease.
Otsuka's therapeutic drugs around the world
In the field of oncology, Busulfex, a conditioning agent prior to bone marrow transplantation in blood cancer, is now available in over 50 countries through Otsuka Pharmaceutical and its partners. It has become a standard treatment replacing radiotherapy within the bone marrow transplantation regimen.
Otsuka also signed an agreement with ARIAD Pharmaceuticals* to commercialize ARIAD's treatment for resistant and intolerant chronic myeloid leukemia in ten Asian countries and regions including Japan, and to fund future clinical trials in those countries. Sales in Japan began in 2016.
- *Acquired by Takeda in 2017
In the cardiovascular field, the vasopressin V2 receptor antagonist Samsca has achieved good penetration in medical settings thanks to the new value and utility it provides. In 2014, the world's first approval of a treatment for autosomal dominant polycystic kidney disease (ADPKD), an intractable disease with no treatments until now, was obtained for Samsca in Japan. Outside of Japan, it is sold under the global product names JINARC / JYNARQUE. Samsca / JINARC / JYNARQUE is now available in over 40 countries. In 2022, SAMTASU was launched as a prodrug of oral tolvaptan (generic name is tolvaptan sodium phosphate).
In the field of ophthalmology several drugs are available, including the dry-eye treatment Mucosta ophthalmic suspension and the antiglaucoma and anti-intraocular hypertension drugs Mikelan LA, and Mikeluna combination ophthalmic solution.
In the field of dermatology, Moizerto was launched in 2022 as the first topical PDE4 inhibitor approved in Japan for the treatment of atopic dermatitis.
(As of August 2022)
